Thermo Fisher Scientific Inc (TMO) is next scheduled to report earnings on Jul 23, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $5.71.
Heading into this report, the model's fair value estimate sits 12.3% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for TMO from 10 independent valuation methods with sufficient data. 5 place fair value above the current price of $533.00, and 5 place it below. The model-blended estimate lands at $467.20 — a model fair value differential of 12.3% below the current price under these model assumptions. The methods are evenly split, reflecting genuine dispersion in the estimate.
Equity Rank's fundamental strength composite scores TMO at 62.9/100 (B-, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -3.1% per year and gross margin has moved -4.7 pp. Its SAVE composite score has moved +0.5 over the past 30 days.
Thermo Fisher Scientific Inc (TMO) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator